Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $2 | $2 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 15.6% | 31.1% | 18% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 79.3% | 93.9% | 93.3% | 92.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -10.2% | -17.2% | -28.7% | -30.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -10.6% | -19.8% | -32.1% | -34.8% |
| EPS Diluted | -0.3 | -0.48 | -0.64 | -0.6 |
| % Growth | 37.5% | 25% | -6.7% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |